Abstract: The present invention relates to a method for the in vitro diagnosis of stroke and transient ischemic attack (TIA) in an individual, comprising the following steps: (a) measuring the level of proBNP(1-108), or of fragments of proBNP(1-108) comprising a RAPRSP sequence (SEQ ID NO: 1), in a biological sample of the individual; (b) comparing the measured level with a cut-off value; (c) determining therefrom whether a stroke or a TIA has occurred in the individual.

Abstract: A method for the in vitro diagnosis of stroke and transient ischemic attack (TIA) in an individual, including the following steps: (a) measuring the level of proBNP(1-108), or of fragments of proBNP(1-108) including a RAPRSP sequence (SEQ ID NO: 1), in a biological sample of the individual; (b) measuring the level of nucleoside diphosphate kinase A (NDKA) in a biological sample of the individual; (c) comparing the level of proBNP(1-108), or of fragments of proBNP(1-108), and the level of NDKA, with one or several cut-off values; and (d) determining therefrom whether a stroke or a TIA has occurred in the individual.

Abstract: A method for the in vitro diagnosis of stroke and transient ischemic attack (TIA) in an individual, comprising the following steps: (a) measuring the level of proBNP(1-108), or of fragments of proBNP(1-108) comprising a RAPRSP sequence (SEQ ID NO: 1), in a biological sample of the individual; (b) measuring the level of nucleoside diphosphate kinase A (NDKA) in a biological sample of the individual; (c) comparing the level of proBNP(1-108), or of fragments of proBNP(1-108), and the level of NDKA, with one or several cut-off values; and (d) determining therefrom whether a stroke or a TIA has occurred in the individual.

Abstract: The present invention relates to a method for the in vitro diagnosis of stroke and transient ischemic attack (TIA) in an individual, comprising the following steps: (a) measuring the level of proBNP(1-108), or of fragments of proBNP(1-108) comprising a RAPRSP sequence (SEQ ID NO: 1), in a biological sample of the individual; (b) comparing the measured level with a cut-off value; (c) determining therefrom whether a stroke or a TIA has occurred in the individual.

Abstract: The present invention relates to a specific C-peptide assay method which can eliminate all interference due to proinsulin and its intermediates, in particular des-31,32-proinsulin and/or des-64,65-proinsulin. It also relates to antibodies for carrying out this assay.

Abstract: The present invention relates to a specific C-peptide assay method which can eliminate all interference due to proinsulin and its intermediates, in particular des-31,32-proinsulin and/or des-64,65-proinsulin. It also relates to antibodies for carrying out this assay.

Abstract: Liposome reagents used in assays to detect the presence or amount of an analyte in a test sample, particularly where the analyte is antiphospholipid antibodies are described. The liposome reagents comprise a liposome, a ligand chosen to bind specifically with the analyte and associated with the liposome membrane, and a haptenated component associated with the membrane of the liposome where the hapten is chosen to bind specifically to a receptor bound to a solid phase or to a label compound that is an element of a signal detection system and where the liposome reagent is prepared so that during the assay the linkage between the solid phase and ligand of the liposome reagent is maintained.

Abstract: The present invention relates to the detection of a variety of analytes in a patient sample employing liposomes with associated ligand, where the ligand is capable of binding target analyte in that sample. In another aspect of the invention, the assays employ liposomes as a soluble support matrix where at least a portion of the support is associated with the ligand and the ligand is in a confirmation permitting it to bind to target analyte in a patient sample.

Abstract: Stabilized composition of troponin I or T for immunoassays, comprising an aqueous solution containing troponin I or troponin T, 1 to 10 molar equivalents of troponin C per molar equivalent of troponin I or T, and Mg.sup.++ and/or Ca.sup.++ ions, as well as a process for stabilizing a composition of troponin I or T for immunoassays consisting in adding from 1 to 10 molar equivalents or troponin C per molar equivalent of troponin I or T.